Align Capital Partners Closes $340M Continuation Vehicle for Proceed

Align Capital Partners just closed a $340 million continuation vehicle for Proceed Innovative, a healthcare technology platform the firm has backed since 2019. The deal — structured through a newly formed vehicle led by Align's Fund V strategy — keeps the asset in-house while offering existing limited partners a choice: roll your stake into the new fund or take liquidity now and walk away.

It's the latest sign that continuation vehicles have moved from niche restructuring tool to standard playbook for PE firms betting they can squeeze more value out of a platform if they just get a little more time. The question is whether Align's LPs see it the same way — or whether this is a polite way of saying the exit market wasn't cooperating.

Proceed operates in the clinical decision support space, providing software that helps healthcare providers manage complex patient workflows, prior authorization processes, and compliance requirements. The company has grown through acquisition under Align's ownership, stitching together specialized point solutions into a broader platform play. Align originally backed Proceed in 2019 out of its fourth fund, which is now six years into its lifecycle and approaching the window where LPs expect distributions.

The continuation vehicle solves that tension. LPs who want out can sell to the new vehicle at what Align describes as a fair market valuation. Those who believe in the next leg of growth can roll their stakes forward, alongside new capital from Align's Fund V and potentially other institutional investors. The firm stays in control, the company stays off the market, and the clock resets.

Continuation vehicles — sometimes called GP-led secondaries — have exploded in use over the past five years. Jefferies' 2024 Global Secondary Market Review estimates that GP-led transactions accounted for roughly $60 billion in volume in 2023, up from under $20 billion in 2019. The structure has become a standard tool for firms managing older funds with strong assets that haven't yet found the right exit window.

The logic is straightforward. If you own a business that's performing well but the M&A market is soft, the IPO window is closed, and your fund is aging out, you have three options: sell at a discount, distribute the asset in-kind to LPs (who hate that), or structure a continuation vehicle that lets you hold longer while giving LPs liquidity. Option three has become the path of least resistance.

For Align, the decision to move Proceed into a continuation vehicle reflects both the strength of the asset and the reality of the exit environment. Healthcare software businesses have seen exit multiples compress over the past 18 months as public market comps cooled and strategic buyers became more selective. Waiting another 12-24 months to sell could mean better pricing — if the thesis holds.

But continuation vehicles aren't without controversy. Critics argue they create conflicts of interest — the GP sets the valuation, controls the process, and benefits from extending the hold period even if LPs would prefer cash now. The SEC has increased scrutiny of GP-led secondaries in recent years, particularly around disclosure, fairness opinions, and whether LPs are getting a legitimate choice or being pressured to roll.

Proceed's business sits in a messy part of the healthcare stack: the layer between payers, providers, and patients where prior authorization requests, utilization management, and clinical documentation requirements pile up. The company's software automates parts of that workflow, pulling data from electronic health records, cross-referencing payer policies, and flagging cases that need review before treatment can proceed.

It's not sexy. But it's critical infrastructure in a system where administrative costs account for roughly 25% of total healthcare spending. Hospitals and health systems need tools like Proceed because the alternative is armies of nurses and case managers manually checking payer rules and filling out forms — work that delays care and burns money.

Under Align's ownership, Proceed has pursued a buy-and-build strategy, acquiring smaller software companies that serve adjacent use cases and integrating them into a broader platform. That strategy creates value by cross-selling into a shared customer base and reducing redundant overhead. But it also creates complexity — multiple products, integration work still underway, and a customer base that's not yet fully consolidated onto a single platform.

That complexity makes Proceed harder to sell. Strategic buyers want clean stories and predictable integration paths. Financial buyers want platforms that can scale without heavy reinvestment. Proceed is somewhere in the middle: real revenue, real customers, real growth — but still a work in progress. The continuation vehicle buys time to finish the build.

The exact split isn't disclosed, but the $340 million figure represents the total enterprise value implied by the transaction — not just fresh capital. That number includes the value assigned to rolled LP stakes, the buyout price for exiting LPs, and any new equity Align is committing from Fund V. The structure effectively resets the cost basis for the firm's newest fund while crystallizing a return for LPs who want liquidity.

Align hasn't disclosed Proceed's revenue or EBITDA, but healthcare software assets at the mid-market scale typically trade between 8-15x EBITDA depending on growth rate, recurring revenue mix, and customer concentration. If Proceed is generating $25-35 million in EBITDA — a reasonable estimate for a business supporting a $340 million equity check at standard leverage ratios — the implied valuation suggests the company has either grown significantly under Align's ownership or the firm is paying up to retain the asset. Or both.

The bull case for extending the hold is straightforward. Healthcare administrative costs aren't going away. Payer policies are getting more complex, not simpler. Providers are under margin pressure and looking for software that reduces manual work and speeds up revenue cycle processes. Proceed is positioned in the middle of all that, with sticky customers and recurring revenue.

The company also benefits from tailwinds around prior authorization reform. Several states have passed laws requiring faster payer responses and more transparency in utilization management decisions. That regulatory pressure creates demand for automation tools that help both sides comply without adding headcount.

But the risks are real. Healthcare IT is crowded. Electronic health record vendors like Epic and Cerner are building more of this functionality natively, which could commoditize third-party tools. Reimbursement pressure on hospitals means IT budgets are tight, and selling cycles are long. And the buy-and-build strategy only works if the acquired companies integrate cleanly — if they don't, you end up with a portfolio of subscale products rather than a platform.

There's also the execution risk inherent in continuation vehicles themselves. Align now has to deliver a return on a stepped-up basis — the Fund V capital is going in at today's valuation, which means the exit multiple has to expand or the business has to grow significantly to generate alpha. If the exit market stays flat or Proceed's growth slows, the math gets harder.

For LPs in Align's Fund IV, the continuation vehicle is a forced choice. Take liquidity now at a valuation set by the GP, or roll into a new fund with a longer timeline and uncertain exit. Some will welcome the option — especially those who still believe in the asset and want exposure. Others will see it as the GP kicking the can down the road because the exit market wasn't favorable.

The fairness of that choice depends heavily on process. Best practices for GP-led secondaries — outlined by the Institutional Limited Partners Association (ILPA) — include independent valuation, LP advisory committee involvement, and genuine optionality for LPs to exit without penalty. If Align followed those guidelines, the deal is defensible. If it didn't, LPs have reason to be skeptical.

Align Capital Partners is a Baltimore-based middle-market firm focused on healthcare, business services, and software. The firm typically writes $50-150 million equity checks into companies with $10-50 million in EBITDA, where it can take control and drive operational improvements. The firm closed its fifth fund at $1.1 billion in 2023, positioning it to continue the strategy with more dry powder.

Proceed is one of several healthcare software assets in the Align portfolio. The firm has historically focused on vertical software businesses serving niche healthcare workflows — revenue cycle management, credentialing, compliance, data analytics. These aren't businesses that generate TechCrunch headlines, but they're often sticky, profitable, and valued by strategic buyers once they reach scale.

The continuation vehicle for Proceed signals that Align sees more value to create before selling. Whether that's through additional acquisitions, product development, or simply riding out a tough exit market until multiples recover is unclear. What's clear is that the firm is betting Fund V capital that another 2-3 years of ownership will deliver a better outcome than selling today.

That bet might prove right. Or it might prove that continuation vehicles are what happens when firms can't admit the exit window closed.

The immediate next step is integration. Align will need to close any outstanding LP elections, finalize the capital structure for the new vehicle, and make sure Proceed's management team is aligned around the extended timeline. That last part matters more than it might seem — continuation vehicles often come with management rollover expectations, and if key executives were expecting liquidity in 2024 or 2025, resetting that clock can create friction.

On the business side, the key question is whether Proceed can continue the buy-and-build strategy or whether it needs to focus on organic growth and profitability. The continuation vehicle provides capital for either path, but the strategic choice will determine the exit multiple. Roll-ups get valued on platform logic — integrated products, shared infrastructure, consolidated customer base. If Proceed is still a collection of subscale products in three years, it'll be harder to sell.

Broader healthcare IT M&A will also matter. If strategic buyers like Oracle (which acquired Cerner) or private equity-backed platforms like Waystar start consolidating the prior authorization and utilization management space, Proceed could become an acquisition target. If that market stays quiet, Align will need to either take the company public (unlikely at this scale) or sell to another PE firm — which reintroduces all the same exit timing questions that led to the continuation vehicle in the first place.

The other variable is regulatory. If prior authorization reform accelerates at the federal level, the tailwinds for Proceed's software get stronger. If CMS or private payers roll back utilization management requirements, the opposite happens. Healthcare policy moves slowly, but when it moves, it reshapes entire software categories.

Align's move with Proceed is part of a larger trend reshaping how private equity funds manage their portfolios. Continuation vehicles are no longer a sign of distress — they're a standard tool for extending hold periods on assets that need more time. But that normalization raises uncomfortable questions about whether the traditional PE fund model still works.

The core tension is this: LPs commit capital to 10-year funds expecting distributions within 5-7 years. GPs raise those funds knowing that some assets will take longer to mature. When exits don't materialize on schedule, something has to give. Historically, that meant selling at a discount or grinding it out until a buyer emerged. Now, it means raising a new fund to buy your own portfolio company.

The shift is dramatic. GP-led deals have tripled in five years while LP-led volume has contracted. That tells you two things: GPs have figured out how to use secondaries as a portfolio management tool, and LPs are either accepting that reality or don't have better options.

The risk is that continuation vehicles become a way to delay accountability. If a GP can always raise a new vehicle to buy more time, when does the clock ever run out? And if the valuation for the continuation vehicle is set by the same GP who needs the deal to close, how do LPs know they're getting a fair shake?

The Align-Proceed deal is also a data point on the state of healthcare software exits. If a well-regarded middle-market firm with a performing asset chooses a continuation vehicle over a sale, that tells you something about buyer appetite. Either the bids weren't there, the bids were too low, or the firm genuinely believes it can generate a better return by holding longer. All three could be true.

Healthcare IT M&A has been uneven. Bain's 2024 Global Healthcare Private Equity Report notes that while deal volume remains strong, valuation multiples for software companies have compressed by 20-30% from 2021 peaks. Strategic buyers are being more selective, focusing on platforms with clear ROI and fast payback periods. Subscale point solutions — even good ones — are harder to sell.

That creates an opening for firms willing to do the integration work themselves. If you can roll up three or four subscale products into a single platform, you can sell the whole thing at a platform multiple. That's the bet Align is making with Proceed. Whether it pays off depends on execution, market timing, and a little luck.

What's certain is that continuation vehicles are here to stay. They've moved from exception to standard practice, and firms that master the structure will have an edge in managing portfolio companies through choppy exit markets. For LPs, the challenge is making sure those vehicles serve their interests — not just the GP's.

Align hasn't disclosed how many LPs elected to roll versus exit, what the fairness opinion process looked like, or what specific milestones Proceed needs to hit to justify the extended hold. Those details matter. If 80% of LPs rolled, that's a vote of confidence. If 80% took liquidity, that's a different signal.

The company's growth trajectory also remains opaque. Is Proceed growing 20% annually, or 40%? Is it profitable, or still investing heavily in product development and M&A? The answers determine whether the continuation vehicle was opportunistic or necessary.

And then there's the counterfactual: what would a sale have looked like in today's market? If Align could have exited at 12x EBITDA but chose to hold for a potential 15x in three years, that's a calculated risk. If the best offer was 8x and the continuation vehicle was the only way to avoid a down round, that's a different story.

We won't know which it was until the next exit. That's the thing about continuation vehicles — they buy time, but they don't answer the underlying question of whether the business is worth what the GP thinks it's worth. They just push that reckoning down the road.